Insmed/$INSM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Insmed
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
Ticker
$INSM
Sector
Primary listing
Employees
1,664
Headquarters
Website
Insmed Metrics
BasicAdvanced
$23bn
-
-$5.70
0.89
-
Price and volume
Market cap
$23bn
Beta
0.89
52-week high
$212.75
52-week low
$70.57
Average daily volume
3.6m
Financial strength
Current ratio
4.469
Quick ratio
3.884
Long term debt to equity
104.137
Total debt to equity
105.336
Interest coverage (TTM)
-11.73%
Profitability
EBITDA (TTM)
-949.036
Gross margin (TTM)
81.81%
Net profit margin (TTM)
-144.44%
Operating margin (TTM)
-117.77%
Effective tax rate (TTM)
-0.47%
Revenue per employee (TTM)
$490,000
Management effectiveness
Return on assets (TTM)
-31.11%
Return on equity (TTM)
-294.46%
Valuation
Price to revenue (TTM)
26.317
Price to book
31.9
Price to tangible book (TTM)
45.43
Price to free cash flow (TTM)
-22.313
Free cash flow yield (TTM)
-4.48%
Free cash flow per share (TTM)
-4.655
Growth
Revenue change (TTM)
115.09%
Earnings per share change (TTM)
-3.09%
3-year revenue growth (CAGR)
47.10%
3-year earnings per share growth (CAGR)
9.95%
10-year earnings per share growth (CAGR)
10.95%
What the Analysts think about Insmed
Analyst ratings (Buy, Hold, Sell) for Insmed stock.
Insmed Financial Performance
Revenues and expenses
Insmed Earnings Performance
Company profitability
Insmed News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs